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Abstract
Background: Multiple sclerosis (MS) is an immune mediated demyelinating disease of the central nervous system (CNS). A
potential new therapeutic approach for MS is cell transplantation which may promote remyelination and suppress the
inflammatory process.
Methods: We transplanted human embryonic stem cells (hESC)-derived early multipotent neural precursors (NPs) into the
brain ventricles of mice induced with experimental autoimmune encephalomyelitis (EAE), the animal model of MS. We
studied the effect of the transplanted NPs on the functional and pathological manifestations of the disease.
Results: Transplanted hESC-derived NPs significantly reduced the clinical signs of EAE. Histological examination showed
migration of the transplanted NPs to the host white matter, however, differentiation to mature oligodendrocytes and
remyelination were negligible. Time course analysis of the evolution and progression of CNS inflammation and tissue injury
showed an attenuation of the inflammatory process in transplanted animals, which was correlated with the reduction of
both axonal damage and demyelination. Co-culture experiments showed that hESC-derived NPs inhibited the activation
and proliferation of lymph node–derived T cells in response to nonspecific polyclonal stimuli.
Conclusions: The therapeutic effect of transplantation was not related to graft or host remyelination but was mediated by
an immunosuppressive neuroprotective mechanism. The attenuation of EAE by hESC-derived NPs, demonstrated here, may
serve as the first step towards further developments of hESC for cell therapy in MS.
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Introduction
Multiple sclerosis (MS), the most common cause of neurological
disability in young adults, is a chronic, multifocal disease of the
CNS. The pathological hallmarks of MS include immune cell
infiltrations, oligodendrocyte death, demyelination and axonal
damage [1–3]. Failure of the CNS to remyelinate MS lesions [4]
and axonal damage [5,6] lead to the irreversible functional decline
of MS patients [7,8].
While cell transplantation therapy of MS was initially suggested
for oligodendroglial cell replacement and myelin regeneration [9],
recent studies have focused on the anti-inflammatory effects of
neural precursor cells (NPs). Transplantation of mouse brain-
derived NPs into the CNS of rodents with experimental
autoimmune encephalomyelitis (EAE), the animal model of MS,
attenuated the brain inflammatory process and severity of clinical
disease [10–12]. Since demyelination and acute axonal injury in
MS are considered to result mainly from the acute inflammatory
process, it raises the notion that the neuroprotective effect of
transplanted NPs in EAE is mediated, at least in part, through the
attenuation of the inflammatory process and prevention of its
secondary neurodegenerative effects.
Human embryonic stem cells (hESC) may potentially serve as
an unlimited source of neural cells for transplantation in
neurological disorders, such as MS. Here we transplanted
hESC-derived NPs into the cerebral ventricles of EAE mice. We
show here for the first time that transplantation of hESC-derived
NPs attenuates the clinical signs of EAE and reduces CNS
inflammation and tissue injury. Moreover, we show that the
therapeutic effect of the transplanted NPs was not mediated by
graft- or host-derived remyelination, but by the suppression of the
acute phase of the inflammatory process in the transplanted- EAE
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therefore conclude that transplanted hESC-derived NPs exert a
neuroprotective effect on the CNS of EAE mice.
Results
hESC-derived NPs express markers of neural precursor
cells and differentiate in-vitro mainly into neurons and
astrocytes
Highly enriched cultures of NPs were derived from hESCs and
propagated as spheres according to our previously published
protocol [13]. Briefly, clusters of hESCs were cultured as floating
aggregates in defined medium, supplemented with the bone
morphogenetic protein antagonist, noggin, basic fibroblast growth
factor (bFGF) and epidermal growth factor (EGF). Under these
culture conditions the cell-clusters developed into spheres that
were mainly comprised of NPs. After 7–9 weeks of propagation,
prior to transplantation into the brains of EAE mice, we
characterized the phenotype and in vitro differentiation potential
of the cells within the spheres. The spheres were highly enriched
with uncommitted NPs, as indicated by the expression of nestin,
polysialylated neural cell adhesion molecule (PSA-NCAM),
Musashi and A2B5 by over 90% of the cells (Fig. 1). When the
human neural sphere cells were plated on fibronectin, in the
absence of growth factors, and allowed to differentiate for seven
days, they gave rise mainly to neurons and astrocytes, as indicated
by the expression of the neuronal marker bIII tubulin and the
astrocyte marker glial fibrillary acidic protein (GFAP) by 6769%
and 1264% of the differentiating cells respectively (Fig. 1). Cells
expressing the oligodendroglial markers, O4 and galactocerebro-
side (GalC) were not observed.
The clinical course of EAE is significantly milder in NP-
transplanted as compared to control mice
EAE was induced in 6–7 week old female C57B/6 mice by
immunization with purified myelin oligodendrocyte glycoprotein
(MOG) peptide as previously described [14]. Seven days after EAE
induction, hESC-derived neural spheres were engrafted after
partial disaggregation into the lateral brain ventricles of the MOG
EAE mice (n=15). In some experiments the spheres were derived
from green fluorescent protein (GFP) expressing hESCs to
facilitate the identification of transplanted cells in vivo. The spheres’
culture medium was transplanted into the ventricles of control
EAE mice (n=21). Both animal groups received cyclosporine daily
from the day of transplantation. In preliminary experiments we
demonstrated that daily cyclosporine treatment, with a dose that
Figure 1. Characterization of the hESC-derived spheres prior to transplantation. Spheres enriched for NPs were developed from hESCs
that were cultured for 3 weeks as free floating clusters in serum-free medium supplemented with BFGF, EGF and noggin. The spheres were further
expanded for 4–6 weeks in the same medium supplemented with bFGF and EGF before transplantation. For in-vitro characterization spheres were
triturated and plated on fibronectin-coated coverslips. Immunofluorescent stainings, 2 hours after plating, demonstrated that the majority of the cells
within the spheres were immunoreactive with anti-A2B5 (A), -Musashi (B), -Nestin (C) and -PSA-NCAM (D). To induce differentiation, the plated cells
were further cultured 7 days in the absence of mitogens. Immunofluorescent stainings showed that the NPs differentiated mainly into bIII tubulin-
expressing neurons (E) and GFAP expressing astrocytes (F). Cells expressing oligodendroglial markers were not observed. Nuclei in A–F are
counterstained with DAPI (blue). Scale bars: 15 mm.
doi:10.1371/journal.pone.0003145.g001
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effect on the clinical and pathological course of MOG EAE (data
not shown). The NPs and vehicle transplanted mice were scored
daily for clinical signs of EAE during a 43 day period (Fig. 2).
Statistical analysis of the clinical scores revealed that the clinical
signs of EAE were significantly attenuated in NP-transplanted as
compared to control EAE mice. Both the maximal clinical scores
and the cumulative scores were significantly reduced in the NP-
transplanted animals (Table 1).
Transplanted NPs differentiate in EAE brains mainly into
early immature neural cells and do not contribute to
remyelination
Following the 43 day period of clinical follow up, the study and
control animals were sacrificed for histopathological analysis. The
transplanted NPs were identified in brain sections by immunoflu-
orescent stainings for human-specific mitochondria, human
specific nuclear antigens or GFP (Fig. 3). The engrafted human
cells survived and migrated extensively from the lateral ventricles
into white matter areas such as the corpus callosum and the
periventricular white matter, where an inflammatory process was
observed. They were not detected in grey matter areas such as the
subcortical grey matter (Fig. 3A).
Serial hematoxylin and eosin (H&E)-stained sections covering
the entire brain did not reveal teratoma tumors in the transplanted
mice
We further characterized the differentiation of the transplanted
cells in the CNS. The vast majority of the transplanted human
NPs either remained as uncommitted precursors (3366%),
identified by the expression of the RNA binding protein, Musashi
(Fig. 3B) or committed into common bipotential neuronal/
oligodendroglial progenitors, expressing the basic helix-loop-helix
(bHLH) transcription factors olig1 (2864%) and olig2 (31612%)
(Fig. 3C, D). Some transplanted cells further differentiated into
oligodendroglial progenitors, expressing NG2 (Fig. 3F), neuronal
progenitors expressing Ngn2 (Fig. 3E) and astrocytes expressing
GFAP (Fig. 3G). The incidence of differentiation into these three
cell types was ,1% per cell type. However, the differentiation of
the transplanted NPs into mature oligodendrocytes expressing
markers such as GalC (Fig. 3H) was extremely rare (,0.01%).
The extremely limited differentiation of the transplanted NPs
into mature oligodendrocytes in-vivo suggested that their thera-
peutic effect in EAE was not mediated by graft-derived
remyelination. To determine whether transplantation had an
effect on endogenous remyelination we calculated the G ratios
(axon diameter/axon+myelin sheath diameter) of axons from
toluidine blue stained spinal cord semi-thin sections from animals
that were sacrificed 50 days post EAE induction. Axons with a G
ratio.0.8 were considered remyelinated [16,17]. Analysis of the G
ratios values of axons from the NP-transplanted and control
groups (n=5 per group) revealed low percentages (,1%) of
remyelinated axons in both groups (Fig. 3I, J). These findings
suggested that the clinical improvement that was observed in
transplanted animals was not related to enhanced remyelination
neither by donor nor host oligodendroglial cells.
Transplanted hESC-derived NPs attenuate the
inflammatory process and the evolution of host tissue
damage
Given the lack of evidence for myelin regeneration after
transplantation, we hypothesized that the beneficial effect of the
transplanted NPs was mediated through a neuroprotective
mechanism. We and others have recently shown an immunosup-
pressive effect of transplanted, rodent brain-derived NPs that was
accompanied by attenuation of tissue damage in the CNS of EAE
animals [11,12,18]. To determine whether the transplanted
hESC-derived NPs protected the CNS from the detrimental effect
of EAE, by suppressing inflammation and its consequent damage
to the CNS we performed a time course experiment in which we
followed the evolution of the inflammatory process and the tissue
damage and compared it between NP-transplanted and control
EAE mice. Following induction of MOG EAE and transplanta-
tion, as described above, mice from NP-transplanted and control
groups were sacrificed at the following 4 time points, which
represented 4 critical stages in the course of EAE [19]: day 10 in
which immune cells begin to infiltrate the CNS although the
disease does not yet manifest clinically; day 13 in which there are
early clinical signs and inflammation is more robust; day 20 which
represents the peak of the acute phase of MOG EAE; and day 50
which represents the chronic phase. In each time point (n=4–5/
group per time point) we performed histochemical and patholog-
ical analysis of spinal cord sections to quantify the severity of
inflammation, demyelination and axonal damage.
To measure the extent of inflammation, we examined the
numbers of immune cell infiltrations, CD3+ T cells and Mac3+
macrophages/activated microglia per mm
2 of the sections. We
measured the extent of demyelination and axonal injury by
analyzing the percentage of area of the spinal cord sections that
was not stained by luxol fast blue (LFB) and Bielschowsky’s
reagents, respectively.
Figure 2. The clinical course of EAE is attenuated after
transplantation of hESC-derived NPs. hESC-derived NPs were
transplanted into the lateral brain ventricles of EAE mice and the
severity of clinical signs was scored daily. A significant attenuation of
the clinical score was observed in NPs-transplanted animals (&)i n
comparison to vehicle-transplanted control animals (m). The reduced
severity of clinical scores in NP-transplanted animals was evident as
early as the acute phase of the disease (day 19 post-EAE induction). See
material and methods section for details regarding the clinical scoring
system.
doi:10.1371/journal.pone.0003145.g002
Table 1. Transplantation of hESC-derived NPs significantly
attenuates the clinical severity of EAE.
NP-transplanted Control EAE P value
Maximal score 2.6561.32 3.9561.25 0.0044
Cumulative score 58.06653.57 93.89651.58 0.0475
doi:10.1371/journal.pone.0003145.t001
hESC-Derived NPs Inhibit EAE
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tissue damage at the acute phase (days 13 and 20) of MOG EAE
by plotting the % of axonal loss against the numbers of CD3+ cells
and Mac3+ cells/mm
2 in NP-transplanted and control mice
(Fig. 4). Regression analysis demonstrated a strong correlation
between the amount of the inflammatory cells and the severity of
tissue damage (R
2=0.86), in the acute phase of EAE (Fig. 4).
Analysis of the evolution of inflammation and tissue damage
showed initial infiltration of immune cells into the CNS in both
groups as early as 10 days post EAE induction. At this stage there
was no histological evidence of demyelination or axonal injury
(Table 2). At day 13, further infiltration of immune cells was
observed in both groups, however, the numbers of CD3+ cells/
mm
2 was significantly reduced in the NP-transplanted in
comparison to the control animals. At this stage, demyelination
and axonal injury were still minimal and similar in both groups
(Fig. 5J, M, Table 2). At day 20, which represents the peak of the
acute phase of MOG EAE, both the numbers of CD3+ cells/mm
2
and Mac3+ cells/mm
2 as well as the number of immune cell
infiltrations/mm
2 were significantly decreased in the NPs-
transplanted animals (Fig. 5A, D, G, Table 2). The differences
between the groups in the numbers of immune cells in the CNS
further increased and were even more prominent at the latest time
point that we examined (day 50; Table 2). In parallel, axonal
damage and demyelinantion became significantly reduced in the
NP-transplanted group as compared to the controls at day 20 post
induction and the difference between the groups in the amount of
axonal damage even increased at the last time point we examined
(Fig. 5J, M, Table 2).
These time course experiments showed the initiation of the
inflammatoryprocessbeforethe demonstration ofCNStissueinjury.
They also suggested that the attenuation of the acute inflammatory
processofEAEbythetransplanted NPscontributed to thedecreased
tissue damage in the CNS. Quantification of apoptotic CD3+ Tc e l l s
in the histopathological sections showed 3.262.4% pyknotic T cell
nuclei in control EAE CNS and 2.762.5% in transplanted CNS.
Thus, the effect of transplantation was not mediated by induction of
T-cell apoptosis in the CNS of EAE mice. The results of the time
course experiments, together with the negligible occurrence of
remyelination that was demonstrated above, suggest that neuropro-
tectiveratherthanregenerativemechanismsunderliethetherapeutic
effect of transplantation.
Figure 3. Transplanted NPs migrate into white matter tracts of EAE brains, differentiate into neural progenitors and do not
promote remyelination. (A–H) Immunofluorescence stainings of brain sections demonstrating the migration and differentiation of transplanted
NPs, which were identified by the expression of human mitochondria (A, C–G), human nuclear antigens (B) and GFP (inset in A, H). (A): The NPs
migrated extensively into white matter areas of the CNS such as the corpus callosum (CC) and were not observed in grey areas such as subcortical
grey matter (SGM). Co-staining against the oligodendroglial marker, O4 (red) was used to identify the white matter. (B–H): Most of the transplanted
cells either remained as uncommitted NPs expressing Musashi (B) or differentiated into early neuronal/oligodendroglial progenitors expressing Olig1
(C) or Olig2 (D). Further differentiation into more committed neuronal progenitors, oligodendrocyte progenitors or astrocytes expressing NGN2 (E),
NG2 (F) and GFAP (G), respectively, was infrequent (,1% of the transplanted cells per each of the cell types). Terminal differentiation of the
transplanted NPs into GalC-expressing mature oligodendrocytes (H) was rare (,0.01% of the transplanted cells). Nuclei in A–H are counterstained
with DAPI (blue). I–J: Toluidine blue stained transverse semi-thin sections of resin embedded spinal cords of NP-transplanted (J) and control (I)
animals. In NP-transplanted animals, there were less demyelinated (arrows in I) and more normally myelinated axons than in controls. In both groups
there were very rare remyelinated axons (G ratio.0.8). Scale bars: 15 mm (A–H), 5 mm (I–J).
doi:10.1371/journal.pone.0003145.g003
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lymph-node cells, in response to concanavalin A
We have shown previously that NPs derived from brains of
newborn mice exhibited a bystander inhibitory effect on T-cell
activation and proliferation in vitro [18]. Here, we analyzed
whether the hESC-derived NPs have similar immunosuppressive
properties by co-culturing them with lymph-node cells (LNCs). We
first used the
3H-thymidine incorporation assay to test whether
hESC-derived NPs exert a direct suppressor effect on the in-vitro
proliferation of LNCs obtained from naı ¨ve C57BL mice. The
human NPs inhibited LNC proliferation in response to concanav-
alin A (ConA), in a dose dependent manner (Fig. 6A). A maximal
effect of 91% inhibition in
3H-thymidine incorporation was
obtained when NPs/LNC ratio of 1:2 was used. We therefore used
this ratio for all the following experiments in-vitro.
We next investigated the effect of hESC-derived NPs on T-cell
activation and proliferation. We measured the induction of IL-2Ra,
a marker for T-cell activation, in Thy1.2+ T cells. In LNCs co-
cultured with the human NPs the fraction of IL-2Ra+ Tc e l l sw a s
reduced by 32%, and a similar decrease was observed in the mean
fluorescence intensity of IL-2Ra (Fig. 6B). In addition, naive LNCs
were labeled with CFSE and stimulated with ConA in the presence
or absence of NPs. FACS analysis showed that the human NPs
reduced the fraction of cycling T cells from 49% to 21% (Fig. 6C).
Discussion
We show here that transplantation of hESC-derived NPs into
the brain ventricles reduces the severity of clinical signs and tissue
damage in the CNS of EAE mice. The beneficial effect is mediated
by a neuroprotective rather than a regenerative mechanism. This
is the first report of the therapeutic potential of NPs derived from
human ESC in an animal model of MS.
The amelioration of EAE without differentiation of the
transplanted cells into myelinating oligodendrocytes suggests that
the beneficial effect of transplantation was not via cell replace-
ment. The hESC-derived NPs used in our study, as opposed to
neural precursors derived from postnatal brains, rarely differen-
tiate into oligodendroglial cells, unless they are specifically directed
to this fate in-vitro [20]. Thus, the negligible differentiation of the
NPs into mature oligodendrocytes both in-vitro and in-vivo indicates
that remyelination by the transplanted cells was very unlikely.
Another mechanism by which transplanted cells might exert a
therapeutic effect in EAE is by enhancing host remyelination. It
was previously shown that NPs express a wide range of
neurotrophic, and mitogenic factors, such as bFGF and platelet-
derived growth factor (PDGF), which stimulate recruitment and
proliferation of endogenous oligodendrocyte progenitors. Further-
more, NPs also express several factors that increase oligodendro-
cyte survival [21,22]. However, our analysis showed that
remyelination was rare, and could be demonstrated in less than
1% of the axons from both transplanted and control EAE groups.
The very limited remyelinatin in MOG 35–55 EAE C57BL/6
mice is related to the extensive axonal injury in this specific model.
Therefore, regenerative properties of hESC-derived NPs, whether
directly or by inducing endogenous remyelination will need to be
examined in other experimental models of MS. In summary, our
findings indicate that the beneficial effect of transplantation was
mediated by a non regenerative, neuroprotective mechanism.
Recent studies showed that transplanted rodent brain-derived
NPs suppress CNS inflammation in EAE [10–12], and suggested
that they exert immunosuppression either via a non-specific
bystander inhibitory effect on T-cell activation [18] or through a
specific immunomodulatory mechanism [12]. To demonstrate that
Figure 4. The extent of the inflammatory process strongly
correlates with the severity of tissue damage in the acute
phase of EAE. NP- transplanted and control mice were sacrificed at 10,
13, 20 and 50 days post EAE induction for pathological analysis of
inflammation and tissue damage. Linear-regression analysis of the
numbers of inflammatory cells and the extent of axonal loss in both NP-
transplanted and control EAE mice at 13 and 20 days post EAE
induction showed a strong correlation between the numbers of T cells
and macrophages per mm
2 and the percentage of axonal loss.
doi:10.1371/journal.pone.0003145.g004
Table 2. Histopathological analyses of inflammatory
parameters, demyelination and axonal damage in the spinal
cord of C57BL/6 mice at 10, 13, 20 and 50 days after MOG35–
55 EAE induction.
Control EAE NP-transplanted P value
Infiltrations/mm
2
day 10 0.1860.2 0.160.13 0.5
day 13 1.4360.5 1.1560.4 0.32
day 20 7.161.4 5.2260.6 0.044
day 50 5.160.9 2.4160.7 0.006
T-cells/mm
2
day 10 2.562.9 1.6662.3 0.65
day 13 19.1664.2 14.6664.3 0.047
day 20 152.9622.7 120.2611.1 0.016
day 50 108.05620.9 57.29613 0.029
Macrophages/mm
2
day 10 4.79663 . 5 64.8 0.73
day 13 40.268.5 34.1665.8 0.24
day 20 240632.9 190619.8 0.027
day 50 179.44615.9 106.04622.5 0.005
% Axonal injury
day 10 00 -
day 13 1.360.57 1.2360.53 0.758
day 20 4.6561 3.4160.4 0.038
day 50 5.2260.83 3.5860.25 0.024
% Demyelination
day 10 00 -
day 13 0.6860.15 0.660.14 0.409
day 20 4.260.36 2.8260.5 0.002
day 50 4.3660.24 2.85601.4 0.002
doi:10.1371/journal.pone.0003145.t002
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damage contributed to the neuroprotective effect that was
observed in the present experiments, we studied here for the first
time the progression of the inflammatory process and the tissue
damage in a time course experiment. An initial step of the acute
inflammatory process in EAE is T-cell infiltration which triggers
macrophage invasion and microglia activation. We showed a
significant reduction in the number of infiltrating T-cells in the
spinal cord of NP-transplanted animals at an early stage of the
acute phase of EAE, when tissue damage was minor and similar in
both study and control groups. This was followed by a significant
attenuation of the acute and chronic inflammatory processes in the
NP-transplanted mice, which correlated with a significant
reduction in the acute tissue damage and subsequent chronic
tissue loss. Therefore, this longitudinal study provides a potential
link between the immunosuppressive effect of the transplanted NPs
and the protection from tissue injury in MOG35–55 EAE. We
further analyzed the immunosuppressive effect of the human NPs
in co-culture experiments. These indicated a generalized bystand-
er inhibitory effect of the human NPs on T cell activation and
proliferation, similar to the effect of rodent brain derived neural
precursors [18]. Further studies are required to determine the
molecular mechanisms that underlie the immunosuppressive
effects of hESC-derived NPs and whether they are shared with
other cell types.
Cell therapy in MS is rapidly approaching a clinical phase.
Candidatesinclude bonemarrow stromalcells[23],adultNPs[9,12]
and hESC-derived NPs.Wehave recently shown that hESC-derived
NPs migrate efficiently and integrate well in white matter tracts of
EAE mice, similar to rodent NPs [24]. This property and the ability
of NPs to appropriately respond to the micro-environment at the site
of transplantation [25] may be beneficial for their long term survival
and function, as compared to non-neural cells. In addition, protocols
to direct the differentiation of hESC into oligodendroglial cells were
recently established, enabling them to be utilized as a source of
remyelinating cells in myelin basic protein (MBP)-deficient shiverer
mice [26,27] and in a model of focal spinal cord lesion [28].
Therefore, combining the anti-inflammatory effect of hESC-derived
Figure 5. Attenuation of the progression of inflammation and tissue damage in the CNS of NPs-transplanted mice. Pathological
examination of spinal cord sections from NP-transplanted and control mice were performed at 10, 13, 20 and 50 days post EAE induction to evaluate
CNS inflammation, demyelination and axonal damage. In NP-transplanted mice an attenuation of the number of immune-cell infiltrates (A), T cells (D)
and macrophages/activated microglia (G) per mm
2 was evident from day 13 post EAE induction and became significant at days 20 and 50.
Demyelination and axonal damage, which were analyzed by loss of Kluver Barrera (J), and Bielschowsky staining (M), respectively, were both
significantly reduced at day 20 and 50 post EAE induction. The differences between the study and control groups in the severity of all parameters
gradually increased with time. Representative day 20 images of H&E staining (B, C), immunostaining for CD3 (E, F) and Mac3 (H, I), Kluver Barrera
staining (K, L) and Bielschowsky silver staining (N, O). * P,0.05. Scale bars: 100 mm.
doi:10.1371/journal.pone.0003145.g005
hESC-Derived NPs Inhibit EAE
PLoS ONE | www.plosone.org 6 September 2008 | Volume 3 | Issue 9 | e3145Figure 6. Direct suppressive effects of hESC-derived NPs on lymph node cells (LNCs) and T cells derived from naı ¨ve C57BL mice.
LNCs derived from naı ¨ve mice were co-cultured with NPs and activated with ConA. The NPs suppressed
3H-thymidine incorporation into the activated
LNCs in a dose-dependent manner (A). FACS analysis of interleukin-2 receptor a (IL-2Ra; CD25) expression after 24 hours of ConA-stimulation showed
that human NPs inhibited the activation of Thy1.2+ T cells as determined by the fraction of labeled cells and by mean fluorescent intensity (MFI) (B).
FACS analysis of CFSE labeled LNCs after 72 hours of ConA stimulation showed that co-culturing with the human NPs inhibited the proliferation of
Thy1.2+ T cells. The fraction of T cells that have proliferated and therefore diluted the CFSE fluorescence (within the rectangle) was reduced in the
presence of the human NPs (C).
doi:10.1371/journal.pone.0003145.g006
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from hESC may provide an advantage to hESC-based cell therapy
over existing conventional immunosuppressive/immunomodulatory
treatments, as well as over non-neural sources of cells for
transplantation in MS.
In conclusion, this study is the first to demonstrate a beneficial
anti-inflammatory and neuroprotective effect of hESC- derived
NPs leading to clinical and pathological amelioration in a relevant
model of MS. These data may serve as the platform for further
developments that may eventually allow the use of hESC for
transplantation in MS.
Materials and Methods
hESC culture: hESC (HES-1 cell line) with a stable normal
(46XX) karyotype were cultured on human foreskin feeders in
serum free medium as described [29] and were passaged weekly by
treatment with collagenase IV (1 mg/ml for 20 min at 37uC).
Generation of highly enriched populations of NPs for
transplantation: wild type and cloned genetically-modified
hESCs that were infected by a lentiviral vector expressing eGFP
under the human EF1a promoter [30] were used for derivation of
NPs for transplantation into EAE mice. Colonies of undifferen-
tiated hESCs were removed from the feeders by treatment with
collagenase IV (1 mg/ml for 20 min at 37uC), transferred to 24-
well culture dishes (Costar; Corning, Inc., Corning, NY, USA),
and cultured in suspension in a chemically-defined neural
precursor medium (NPM) consisting of DMEM/F12 (1:1), B27
supplement (1:50), 2 mM glutamine, 50 units/ml penicillin,
50 mg/ml streptomycin (Gibco), 20 ng/ml rh-bFGF, and 20 ng/
ml rh-EGF (both from R&D Systems Inc., Minneapolis, MN).
Recombinant mouse noggin (700 ng/ml; R&D) was added to the
NPM to promote neural differentiation as described [13]. After
three weeks under these culture conditions the neural spheres that
developed were further expanded in NPM bFGF and EGF in the
absence of noggin, for 5 more weeks before transplantation.
Animals: For MOG EAE induction and transplantation
experiments, 6–7 week old C57BL female mice were supplied by
Harlan laboratories and were maintained in a specific pathogen
free (SPF) unit.
MOG EAE induction: EAE was induced in 6–7 week old
female C57BL mice by immunization with an emulsion containing
300 mg of purified MOG peptide (MEVGWYRSPFSRVVH-
LYRNGK, corresponding to residues 35–55) in PBS and an equal
volume of complete Freund’s adjuvant containing 5 mg H37RA
(Difco). 0.2 ml of the inoculum was injected subcutaneously at day
of induction (day 0) and at day 7. In addition, 300 ng of Bordetella
pertusis toxin (Sigma) in 0.2 ml PBS was injected intraperitoneally
at day of induction and at day 2.
Clinical evaluations of EAE: After EAE induction, mice
were scored daily for EAE clinical signs, according to the following
score: 0, asymptomatic; 1, partial loss of tail tonicity; 2, atonic tail;
3, hind-leg weakness and/or difficulty in rolling over; 4, hind-leg
paralysis; 5, four-leg paralysis; 6, death due to EAE.
At the end of the follow-up period, the maximal score and the
cumulative score of each animal were calculated. Maximal clinical
score was calculated as the mean of the maximal clinical scores
during the experimental period. Cumulative clinical score was
calculated as the mean of the sum of the daily clinical scores
during the experimental period.
Transplantation of NPs: Seven days post EAE induction
(day 7) the mice were anesthetized with intraperitoneal injection of
pentobarbital (0.6 mg/10 gr) and were fixed in a stereotactic
device. Quantities of 5610
5 cells or NPM in a volume of 7.5 ml
were injected into each lateral ventricle.
Tissue fixation and histological preparation: For
analysis of the in-vivo localization and differentiation of the
transplanted cells and for analysis of remyelination, EAE animals
were sacrificed at the end of the follow-up period (50 days post-
EAE induction). For histopathological analysis of the progression
of inflammation and tissue damage in the time course experiment
animals were sacrificed at 10, 13, 20 and 50 days post EAE
induction (n=4–5 per group at each time point). Animals were
anesthetized with a lethal dose of pentobarbital and brains and
spinal cords were perfused via the ascending aorta with ice-cold
PBS followed by cold 4% paraformaldehyde (PFA) in PBS. The
tissues were dissected and post-fixed by immersion in the same
fixative for 24 h at 4uC. Brains were deep frozen in liquid nitrogen
and cut to serial 6–8 mm axial and longitudinal sections and spinal
cords were embedded in paraffin for pathological analysis.
Pathological analysis: Analysis of inflammation, demyelin-
ation and axonal damage was performed on 5 mm paraffin-
embedded serial transverse sections in three different rostrocaudal
levels of the spinal cord. For histochemical analysis, sections were
stained with H&E, LFB/periodic-acid Schiff staining, and
Bielschowsky silver impregnation to assess inflammation, demye-
lination, and axonal pathology, respectively. In adjacent serial
sections, immunohistochemistry was performed with antibodies
against macrophages/activated microglia (rat anti-mouse Mac3,
01781D, clone M3/84; 1:200; Pharmingen, San Diego, CA) and
T cells (rat anti-human CD3, MCA 1477; 1:400, Serotec, Bicester,
United Kingdom). Primary antibodies were detected by the
avidin-biotin technique using biotin conjugated secondary anti-
bodies. The total average number of positive cells per square
millimeter, in spinal cord cross sections, was counted using a grid
overlay.
Apoptosis of T cells in the CNS was determined morpholog-
ically by the appearance of condensed and fragmented nuclei in
CD3+ cells. The percentage of apoptotic cells was determined in
transplanted and control animals (n=3 in each group) by
morphological analysis of 250 CD3+ cells in random CNS
sections.
Demyelination and axonal damage were assessed in spinal cord
sections by calculating the area of LFB and Bielschowsky silver
staining loss, representing areas of myelin destruction and axonal
loss, respectively. The percentage of demyelinated and axonal
damage areas was determined by counting intersections of the grid
over the demyelinated lesions and the areas of axonal loss.
For the evaluation of remyelination, animals were perfused with
4% gluteraldehyde. The fixed spinal cords were cut into 1 mm
transverse blocks from the cervical, thoracic and lumbar areas.
The blocks were osmicated, dehydrated through an ascending
series of ethanols and embedded in TAAB resin. 1 mm sections
were cut from each block, stained with toluidine blue (Sigma) and
examined by light microscopy.
To determine whether transplantation had an effect on
remyelination, the diameter of axons from toluidine blue stained
spinal cord semi-thin sections was measured, and their G ratios
were calculated (G=axon diameter/(axon+myelin sheath diame-
ter)). The G ratio of intact axons is 0.5–0.8. Since the myelin
sheath is thinner in remyelinated axons, an axon with a G
ratio.0.8 was considered remyelinated.
Immunofluorescent staining of NPs in vitro and in
vivo: The following primary antibodies were used: Rabbit IgG
anti-GFP (1:100, Chemicon), mouse IgG anti-human specific
mitochondria (1:200, Chemicon), mouse IgM anti-A2B5 (1:1,
ATCC), mouse IgM anti-PSA-NCAM (1:200, Chemicon), rabbit
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Chemicon), mouse IgG anti-human nuclei (1:50, Chemicon),
rabbit IgG anti-NG2 (1:50, Chemicon), mouse IgM anti-PDGFRa
(1:20, R&D), rabbit IgG anti-NGN2 (1:300, Chemicon), rabbit
anti-GalC (1:20, Chemicon), mouse IgM anti-O4 (1:20, Chemi-
con), rabbit IgG anti-MAP2 (1:200, Chemicon), mouse IgG anti-b
tubulin III (1:2000, Sigma), rabbit anti-GFAP (1:100, Dako),
rabbit IgG anti-olig1 (1:20, Chemicon) and goat anti-olig2 (1:30,
R&D). Texas red or Alexa 488-conjugated goat anti-mouse IgM
(1:100, Jackson, West Grove, PN), goat anti-rabbit IgG (1:100,
Molecular Probes), goat anti-mouse IgG (1:100, Molecular Probes)
or donkey anti-goat IgG (1:200, Jackson, West Grove, PN) were
used as secondary antibodies, where appropriate.
For in-vitro characterization of the NPs that were generated for
transplantation, small aggregates of NPs were plated on poly-D-
lysine (10 mg/ml) and fibronectin (5 mg/ml; both from Sigma) pre-
coated cover slips in central well plates in NPM without growth
factors. Half of the cultures were fixated in 4% PFA after 2 hours
and stained for A2B5, nestin, Musashi and PSA-NCAM. The rest
of the cultures were fixed after 7 days of differentiation, and
stained for b tubulin III and GFAP. The cell surface markers
NG2, O4 and GalC were stained in living cells followed by
fixation in 4% PFA. The cells were incubated with primary
antibody for 45 min followed by 30 min incubation with a
secondary antibody. Mounting medium containing 4V, 6-
diamidino-2-phenylindole (DAPI; Vector, Burlingame, CA) was
used for nuclei counter staining.
For characterization of the in-vivo location and differentiation of
the transplanted NPs, double immunofluorescent stainings were
performed on 6–8 mm axial frozen brain sections. Human cells
were identified either by the expression of human specific
mitochondrial antigen, human nuclear antigen, direct GFP
fluorescence visualization, or by an anti-GFP antibody. The
sections were incubated with primary antibody overnight at 4uC
followed by 50 min incubation with a secondary antibody at room
temperature.
Images were taken by a fluorescent microscope (Nikon E600,
Kanagawa, Japan) or confocal microscope (Zeiss, Feldbach,
Switzerland). Three hundred cells were scored within random
fields at 61000 magnification. The percentage of each cell
phenotype was determined by dividing the number of positively
stained cells by the total number of GFP+, DAPI stained nuclei.
Co-cultures of hESC-derived NPs and LNCs: Lymph
nodes were excised from naı ¨ve mice. LNCs were cultured as
single-cell suspensions, as described previously [10] with 2.5 mg/
ml ConA or in control medium. NPs were irradiated with 3,000
Rad for 1 minute and then added directly to the LNC culture
medium with non-stimulated or stimulated LNCs (10
5 NPs/2610
5
LNCs)
In-vitro proliferation assay: The proliferation of LNCs
after 72-hour incubation in- vitro was evaluated by means of a
standard
3H-thymidine incorporation assay, as described previ-
ously [10]. In all fluorescent activated cell sorter (FACS)
experiments, cells were pre-coated with anti–mouse CD16/
CD32 (BD Pharmingen,) to block unspecific binding, and T cells
were identified by cell-surface labeling with APC-labeled anti-
Thy1.2 (BD Pharmingen). All samples were analyzed in a
FACSCalibur apparatus using the Cell Quest software (BD
Biosciences, San Jose, CA). The proliferation of T cells obtained
from naive mice was evaluated by FACS analysis for the
incorporation of the cell division tracking dye 5(6)-carboxyfluor-
escein diacetate succinimidyl ester (CFSE), as described previously
[31]. For CFSE FACS analysis, LNCs were pulsed with 3 mM
CFSE (Molecular Probes, Eugene, OR) for 10 minutes, washed,
and further cultured with or without ConA for 72 hours. CFSE-
labeled, non-activated cells were used as control samples. The
fraction of T cells that entered cell cycle was calculated by the
formula:
P total events in cycle n
2n forn§1 ðÞ
P total events in cycle n
2n forn§0 ðÞ
T-cell activation was analyzed by staining with PE-labeled anti-
CD25 (Serotec, Bicestar,United Kingdom) for interleukin-2
receptor a (IL-2Ra).
Statistical analysis: Clinical evaluations of EAE mice and
quantification of the pathological features were performed by
examiner, blinded to the experimental group. The results are
presented as mean6SD. For comparison of clinical and
pathological parameters between experimental and control
groups, student’s t-test was used. For analysis of the relationship
between the inflammatory process and the tissue damage,
regression analysis was used.
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